Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

New Delhi, Feb 5 () Consumer healthcare firm Zydus Wellness on Wednesday reported a consolidated net profit of Rs 4.24 crore for the quarter ended December 31, 2019. The company had reported a net profit of Rs 39.69 crore for the corresponding period of the previous fiscal, Zydus Wellness said in a regulatory filing. The consolidated financial results for the three and nine months ended December 31, 2019 include operations of Heinz India Pvt Ltd which was merged into Zydus Wellness Products Ltd, hence the results are not comparable with those of the previous periods, the company said. Consolidated revenue from operations of the company stood at Rs 332.67 crore for the quarter under consideration. It was Rs 145.41 crore for the same period a year ago. Shares of Zydus Wellness were trading at Rs 1,498.10 per scrip on BSE, down 0.32 per cent from its previous close. AKT DRR

Zydus Wellness Q3 net profit at Rs 4 cr

New Delhi, April 1 () Zydus Group firm Zydus Wellness on Wednesday said it has forayed into hand sanitizer category with the launch of its product under 'Nycil' brand in the country to meet the rising demand due to COVID-19 outbreak. The company had acquired the Nycil brand as part of its acquisition of Heinz India. The company decided to roll out this product in a record time of 12 days, as a response to the current pandemic. Nycil sanitizer consists of neem and aloevera extracts that helps kill 99.9 per cent germs, Zydus Wellness said. "We had acquired the Nycil brand as part of the acquisition of Heinz India. When we worked for extension of Nycil brand, one of the categories that came up was hand sanitizers. We had decided to launch this in 2021," Zydus Wellness CEO Tarun Arora told . However, given the extraordinary times we are living in, the company decided to prepone the launch plans. As there is a need in the country for sanitizers, it was decided to launch it now, he added. "We are in a process of rolling it out across the country. This is the first ever brand extension of Nycil. We have launched in north, and as production ramps up we are in the process of scaling it to all parts of the country," Arora said. The company plans to roll out more than 2 million bottles on a priority basis in next 30 days to be made available across India for medical help providers and general consumption, he added. When asked if the company is also looking at other brand extensions for Nycil, Arora replied in affirmative and said Zydus Wellnes is looking at valuating the timing and preparations for it. On being asked if the company is also facing problems due to the nationwide lockdown, he said, "Right now we are also facing supply chain issues because of the lockdown, but government is helping the industry to smoothen this process. It is a step in the right direction. Local governments are also helping the industry in this." The hand sanitizer is a permanent offering from the company and will continue to exist in the portfolio beyond the current situation, Zydus Wellness said. AKT RVK

COVID-19: Zydus Wellness launches hand sanitizer under Nycil brand to meet growing demand

<ul><li>At 7:45 am, the SGX Nifty was down 1.14%, indicating a negative start for Nifty50. </li><li>Here’s a list of stocks to watch for in trade today. </li><li><a href="https://www.businessinsider.in/">Check out the latest news and updates on Business Insider. </a></li></ul>The Indian stock market is likely to open in red on Thursday, amid the weak sentiments from the global market. At 7:45 am, the SGX Nifty was down 1.14% pointing towards a negative start for Nifty50. In global markets, the US stocks resumed their heavy sell-off amidst weak macroeconomic indicators and overshadowed recovery outlook on Wednesday. The Dow Jones Industrial Average ended up 525.05 points lower, and the S&amp;P 500 was down 2.37%. These are the stocks to watch out for during the trading session on September 24: Zydus Wellness Zydus Wellness board has approved and authorised the opening of the Qualified Institutional Placement issue at ₹1,775.85 per share on September 23. The shares of Zydus Wellness ended 4% lower yesterday. HDFC Limited Housing Development Finance Corporation Ltd (HDFC) is looking to raise up to ₹5,000 crore by issuing bonds on a private placement basis. The issue size for the secured redeemable Non-Convertible Debentures (NCDs) will be ₹2,500 crore with an option to retain oversubscription of up to ₹2,500 crore, it said in a regulatory filing to stock exchanges. The shares of HDFC Limited ended 0.4% lower yesterday. Infrastructure Leasing &amp; Financial Services (<keyword id="6357293" type="UNKNOWN" weightage="20" keywordseo="ILFS">IL&amp;FS</keyword>) The government of India has extended the term of Uday Kotak as non-executive chairman of debt-ridden IL&amp;FS group by one year. Kotak is also the managing director and chief executive officer of Kotak Mahindra Bank. The shares of IL&amp;FS Transportation Networks ended 4% lower yesterday. Tata Consultancy Services IT major Tata Consultancy Services (TCS) along with the US-based Yale University announced the launch of a new framework that could help ensure privacy and trust in peer-to-peer digital networks. The company said this would be a critical element in enhancing blockchain solutions for greater adoption by consumers. The shares of TCS ended 3% lower yesterday. Future Consumer Future Consumer promoter, Future Capital, invoked 36.6 lakh pledged equity shares. The shares of Future Consumer ended 4% lower yesterday. Sun Pharma Sun Pharma voluntarily recalled one lot of RIOMET ER (metformin hydrochloride for extended-release oral suspension), to the consumer level. The reason for the recall by Sun Pharma came after testing showed high levels of N-nitrosodimethylamine (NDMA), which is above the USFDA norms. The shares of Sun Pharma ended 1.3% lower yesterday. ONGC A fire broke out on Thursday morning at ONGC’s Surat plant. According to <a href="https://www.ndtv.com/india-news/massive-fire-breaks-out-at-ongc-plant-in-gujarats-surat-after-gas-pipeline-blast-2300194">reports</a>, three consecutive blasts took place at two terminals of the Hazira-based ONGC plant in Surat at around 3:30 am. The shares of ONGC ended 2.3% lower yesterday. Angel Broking IPO The ₹600 crore IPO of Angel Broking closes today. The issue was subscribed 1.45 times, a retail portion at 2.8 times on day 2, yesterday. SEE ALSO: <a href="https://www.businessinsider.in/business/startups/news/airbnb-ceo-brian-chesky-on-the-companys-ipo-when-the-markets-ready-for-airbnb-it-will-go-public/articleshow/78276873.cms" data-type="tilCustomLink">Airbnb CEO Brian Chesky on the company's IPO⁠— 'When the market's ready for Airbnb, it will go public'</a> <a href="https://www.businessinsider.in/business/corporates/news/tech-mahindra-subsidiary-sells-stake-in-altiostar-to-rakuten-for-45-million/articleshow/78273567.cms" data-type="tilCustomLink">Tech Mahindra subsidiary sells stake in Altiostar to Rakuten for $45 million</a>

Top stocks to watch— TCS, Future Consumer, ONGC, Zydus Wellness, HDFC, IL&FS, Angel Broking, Sun Pharma and others

<keyword id="19914246" type="General" weightage="20" keywordseo="Zydus-Lifesciences" source="keywords" meta.keywordsubtype="org" meta.entityname="Zydus Lifesciences" meta.hostid="261" meta.entityid="Zydus Lifesciences">Zydus Lifesciences</keyword> on Friday said its consolidated <keyword id="19942166" type="General" weightage="20" keywordseo="net-profit" source="keywords">net profit</keyword> surged four-fold to Rs 1,182 crore for the fourth quarter ended March 31, 2024 on higher sales. The drug firm had reported a net profit of Rs 297 crore in the January-March quarter of the 2022-23 fiscal. Revenue from operations rose to Rs 5,534 crore in the period under review from Rs 5,011 crore in the year-ago period, Zydus Lifesciences said in a statement. For the year ended March 31, 2024, the company reported a consolidated net profit of Rs 3,859 crore as compared with Rs 1,960 crore in FY23. Revenue from operations rose to Rs 19,547 crore from Rs 17,237 crore in the 2022-23 fiscal. "Our relentless focus on patient centricity, operational efficiency, strategic investments, and execution of our diversified product portfolio continues to pay off, resulting in a significant improvement in profitability as well," Zydus Lifesciences MD Sharvil Patel said. The company said its board has approved a final dividend of Rs 3 per equity share of Re 1 each, subject to approval of the shareholders. Shares of the company ended 4.28 per cent up at Rs 1,051.90 apiece on the BSE. SEE ALSO:<a href="https://www.businessinsider.in/tech/mobile/webstories/motorola-edge-50-fusion-vs-oneplus-nord-ce-4-price-specs-and-features-compared/slidelist/110197390.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/mobile/webstories/motorola-edge-50-fusion-vs-oneplus-nord-ce-4-price-specs-and-features-compared/slidelist/110197390.cms" target="_blank">Motorola Edge 50 Fusion vs OnePlus Nord CE 4 – price, specs and features compared</a><a href="https://www.businessinsider.in/india/news/average-housing-prices-up-10-in-jan-mar-across-the-top-eight-cities/articleshow/110181627.cms" target="_blank"></a> <a href="https://www.businessinsider.in/india/news/average-housing-prices-up-10-in-jan-mar-across-the-top-eight-cities/articleshow/110181627.cms" target="_blank">Average housing prices up 10% in Jan-Mar across the top eight cities</a><a href="https://www.businessinsider.in/tech/mobile/news/motorola-edge-50-fusion-with-144hz-poled-display-500mah-battery-launched-starting-at-22999/articleshow/110170762.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/mobile/news/motorola-edge-50-fusion-with-144hz-poled-display-500mah-battery-launched-starting-at-22999/articleshow/110170762.cms" target="_blank">Motorola Edge 50 Fusion with 144Hz pOLED display, 5,00mAh battery launched starting at ₹22,999</a>

Zydus Q4 net profit surges 4-fold to ₹1,182 cr; revenue at ₹5,534 cr

(Eds: Adds details about COVID vaccine) New Delhi, Jul 3 () Zydus on Friday said it has received approval from authorities to start human trials for its COVID-19 vaccine contender - the second Indian pharmaceutical firm to get such nod amid a surge in novel coronavirus infections worldwide. The vaccine, ZyCoV-D, showed a "strong immune response" in animal studies, and the antibodies produced were able to completely neutralise the wild type virus, Zydus, part of Cadila Healthcare Ltd, said in a statement. This comes within days of Bharat Biotech's Covaxin vaccine getting approval of the drug regulator to start clinical trials. Over seven vaccines are being researched in India and two of them have got go-ahead to start human clinical trials just this week. Globally, over 100 candidates are being tested on humans but no vaccine has yet been approved. "Zydus has already manufactured clinical good manufacturing practice (GMP) batches of the vaccine candidate and plans to initiate the clinical trials in July 2020 across multiple sites in India in over 1,000 subjects," the company said. ZyCoV-D, developed at the company's Vaccine Technology Centre in Ahmedabad, has now received permission from the Drug Controller General of India (DGCI) - Central Drugs Standard Control Organisation (CDSCO) to initiate phase I/II human clinical trials in India, Cadila Healthcare said. In animal studies, the vaccine was found to elicit a strong immune response in multiple animal species like mice, rats, guinea pigs and rabbits. The antibodies produced by the vaccine were able to completely neutralise the wild type virus in virus neutralisation assay indicating the protective potential of the vaccine candidate, it said. It further said no safety concerns were observed for the vaccine candidate in repeat-dose toxicology studies by both intramuscular and intradermal routes of administration. In rabbits, up to three times the intended human dose was found to be safe, well-tolerated and immunogenic. Zydus said, with its ZyCoV-D, it has successfully established the DNA vaccine platform in India using non-replicating and a non-integrating plasmid carrying the gene of interest making it very safe. The company claimed that the vaccine candidate has no vector response and with the absence of any infectious agent, the platform provides ease of manufacturing the vaccine with minimal biosafety requirements. It is also known to show much-improved vaccine stability and lower cold chain requirements making it easy for transportation to remotest parts of the country, it said. "Furthermore, the platform can be rapidly used to modify the vaccine in a couple of weeks in case the virus mutates to ensure that the vaccine still elicits protection," it added. The company now intends to rapidly ramp up the production capacities of ZyCoV-D at multiple sites and facilities to cater to Indian and global demand. RKL MR

Zydus gets nod for human trials of COVID-19 vaccine

These 8 valuable companies rule their sectors with a huge piece of the pie

New Delhi, Jul 3 () Zydus, a part of the Cadila Healthcare group, on Friday said its indigenously developed COVID-19 vaccine candidate - ZyCoV-D - has successfully completed pre-clinical phase and has received permission from Indian authorities to conduct human trials. "Zydus has already manufactured clinical good manufacturing practice (GMP) batches of the vaccine candidate and plans to initiate the clinical trials in July 2020 across multiple sites in India in over 1,000 subjects," the company said. ZyCoV-D, developed at the company's Vaccine Technology Centre in Ahmedabad, has now received permission from the Drug Controller General of India (DGCI) - Central Drugs Standard Control Organisation (CDSCO) to initiate phase I/II human clinical trials in India, Cadila Healthcare said in a regulatory filing. In animal studies the vaccine was found to elicit a strong immune response in multiple animal species like mice, rats, guinea pigs and rabbits. The antibodies produced by the vaccine were able to completely neutralise the wild type virus in virus neutralisation assay indicating the protective potential of the vaccine candidate, it said. It further said no safety concerns were observed for the vaccine candidate in repeat dose toxicology studies by both intramuscular and intradermal routes of administration. In rabbits, up to three times the intended human dose was found to be safe, well tolerated and immunogenic. Zydus said, with its ZyCoV-D, it has successfully established the DNA vaccine platform in India using non-replicating and non-integrating plasmid carrying the gene of interest making it very safe. The company claimed that the vaccine candidate has no vector response and with absence of any infectious agent, the platform provides ease of manufacturing the vaccine with minimal biosafety requirements. It is also known to show much improved vaccine stability and lower cold chain requirements making it easy for transportation to remotest parts of the country, it said. "Furthermore, the platform can be rapidly used to modify the vaccine in couple of weeks in case the virus mutates to ensure that the vaccine still elicits protection," it added. The company now intends to rapidly ramp up the production capacities of ZyCoV-D at multiple sites and facilities to cater to Indian and global demand. RKL ANS ANS

Zydus says potential COVID-19 vaccine gets DGCI nod for human trials

Ahmedabad, Feb 15 () Pharmaceutical major Zydus Cadila on Saturday said it has initiated an accelerated research programme with multiple teams in India and Europe for developing a vaccine for coronavirus.The first approach deals with development of a DNA vaccine against the major viral membrane protein responsible for the cell entry of the novel corona virus, now called COVID-19, the company said in a statement.The plasm id DNA would be introduced into the host cells, where it would be translated into the viral protein and elicit a strong immune response mediated by the cellular and humoral arms of the human immune system, which play a vital role in protection from disease as well as viral clearance.The second approach deals with development of a live attenuated recombinant measles virus vectored vaccine against COVID-19. The recombinant measles virus (rMV) produced by reverse genetics would express codon-optimised proteins of the novel coronavirus and will induce long-term specific neutralizing antibodies, which will provide protection from the infection."There is an urgent and pressing need to develop a safe and efficacious vaccine that can prevent the spread of this deadly virus. Our researchers are working to bring a speedy solution to this most devastating outbreak in recent times," Zydus Group Chairman Pankaj R Patel said.The Novel Coronavirus outbreak, which started in December 2019, has so far infected over 67,000 people and has claimed over 1,500 lives. RSN BAL

Zydus Cadila launches research prog to develop vaccine for coronavirus

New Delhi, April 7 () Indian pharma industry on Tuesday said there is enough stock of hydroxychloroquine in the country, and drug firms are ready to ramp up the production to meet domestic as well as export requirements.India has decided to partially lift the ban on the export of anti-malarial drug hydroxychloroquine in sync with its global commitment to deal with coronavirus pandemic.On March 25, India had banned the export of hydroxychloroquine in the midst of concerns that the drug could be used to fight COVID-19.India is the largest exporter of the drug.Officials said India would export the drug on a case-by-case basis after meeting all the domestic requirements."India manufactures 70 per cent of the world's supply of hydroxychloroquine. Companies like Zydus Cadila and IPCA are the major manufacturers of hydroxychloroquine in the country," Indian Pharmaceutical Alliance (IPA) Secretary General Sudarshan Jain told .The production capacity is sufficient to meet the current demand. If the need arises, the companies are committed to ramp up production, he added."The government has withdrawn the restrictions on 12 products and its formulations. Various scenarios are being assessed and it will be the endeavour to meet both the domestic demand and export obligation for Paracetamol and hydroxychloroquine," Jain said.The objective is to minimise speculative buying and hoarding in these trying times and ensure balance in distribution for patients and segment who need them, he added.In similar vein, Indian Drug Manufacturers' Association (IDMA) Executive Director Ashok Kumar Madan said: "India needs around 24 million tablets per year as on date for the three indications --- malaria, lupus and rheumatoid arthritis, it was being used".India currently has an annual installed capacity of around 40 metric tonne of active pharmaceutical ingredients (APIs) of hydroxychloroquine. With this capacity, "we can make around 200 million tablets of 200 mg," he added.So this indicates, that India currently has spare available capacity. Now, "we have to see how much would the country's requirements for the drug would grow for both treatment and prevention of COVID-19. The companies have already started ramping the capacity," Madan said.Hydroxychloroquine has suddenly come into limelight after the recommendation for the treatment and prevention of COVID-19, he added. The major API makers for the drug in the country are Zydus, Ipca and Mangalam Drugs. The major formulation makers of hydroxychloroquine are Ipca , Zydus, Wallace Pharmaceuticals and Cipla, Madan said.India exported hydroxycholoroquine API worth USD 1.22 billion in April-January 2019-20. During the same period exports of formulations made from hydroxycholoroquine was at USD 5.50 billion. RR AKT BAL

Enough capacity in country to meet hydroxychloroquine demand: Industry

New Delhi, Mar 3 () Pharmaceutical major Zydus Cadila on Tuesday said it has received approval from the Drug Controller General of India (DCGI) to initiate Phase I clinical trials for a new drug entity intended to treat Rheumatoid Arthritis. The DCGI has approved conducting test on a limited number of patients for investigational new drug ZYBK2, which is a new chemical entity (NCE), the company said in a regulatory filing. ZYBK2 has been specifically designed to inhibit a particular genetic sequence -- HLA-DRBI shared epitope (SE) -- that determines susceptibility of a person to develop Rheumatoid Arthritis (RA). The vast majority of RA patients carry this genetic sequence, it added. The molecule addresses high unmet medical need and has a large market potential for treatment of the disease. Commenting on the development, Zydus Group Chairman Pankaj Patel said, "There is significant unmet medical needs among patients with Rheumatoid Arthritis. Unlike other therapeutic strategies for managing RA, targeting upstream molecular interactions with ZYBK2 is less likely to cause adverse events." He further said: "This clinical trial will seek to find answers if inhibiting HLA-DRBl-mediated effects could provide a safe remedy for treating this debilitating disease." The company said nearly 13 million people are estimated to suffer from RA, which is a progressive, systemic autoimmune disease that affects at least 1 in every 100 people worldwide. Autoimmune diseases cause the body's immune system to mistakenly attack one's own healthy normal tissues. In case of RA, the body's own immune system attacks the lining of joints and can affect other body organs as well, it added. RKL SHWSHW

Zydus Cadila gets DCGI nod for Phase I trial of new drug aimed to treat rheumatoid arthritis

(Eds: Adding more info) New Delhi, Apr 7 () India is the biggest manufacturer of <keyword id="4751090" type="PERSON" weightage="20" keywordseo="Hydroxychloroquine">hydroxychloroquine</keyword>, the anti-malarial drug that is being touted as 'game-changer' in the fight against COVID-19 and is being aggressively sought by US President Donald Trump. The country has the capacity to quickly ramp up the output of hydroxychloroquine. Days after it added the drug to the list of more than two dozen APIs that cannot be exported while officials get a handle on how much will be needed for COVID-19 outbreak in the country, India on Tuesday agreed to lift the ban after Trump sought supplies for the US. India manufactures 70 per cent of the world's supply of hydroxychloroquine, according to Indian Pharmaceutical Alliance (IPA) secretary-general Sudarshan Jain. The country has a production capacity of 40 tonnes of hydroxychloroquine (HCQ) every month, implying 20 crore tablets of 200 mg each. And since the drug is also used to auto-immune diseases like rheumatoid arthritis and lupus, manufacturers have good production capacities that can also be ramped up. Ipca Laboratories, Zydus Cadila and Wallace Pharmaceuticals are top pharma companies manufacturing HCQ in India. Jain says the production capacity is sufficient to meet the current demand and if the need arises, the companies are committed to ramping up production. Recently, the Ministry of Health and Family Welfare had reportedly placed an order for around 10 crore tables of HCQ with Ipca laboratories and Zydus Cadila. The drug is not manufactured in developed nations such as the US because of non-existent malaria. Hydroxychloroquine is very similar to chloroquine, one of the oldest and best-known anti-malarial drugs, but with lesser side-effects. It can be bought over the counter and fairly inexpensive. But its purchase and use has been severely restricted as it was selectively used in the treatment of coronavirus because of its antiviral properties. India gets the active pharmaceutical ingredient (API) that is used to manufacture HCQ from China and supplies so far have been steady. As much as 70 per cent of all the APIs needed by India to manufacture drugs come from China. After Trump stated that the US could "retaliate" if India does not release stocks of the drug, Indian officials said exports of hydroxychloroquine and paracetamol will be allowed depending on availability of stock after meeting domestic requirements and existing orders. Last month, the US Food and Drug Administration (FDA) partially lifted a three-year-old 'import alert' on Ipca's two plants to import the medicine. Zydus Cadila has also received an order from the US. Pharma industry officials said the country has enough stock of HCQ and companies were ready to ramp up the capacity to meet domestic requirements as well as exports. On March 25, India had banned export of HCQ and added it to a list of more than two dozen APIs that can no longer be exported. India is the largest exporter of the drug. Officials said India would export the drug on a case-by-case basis after meeting all the domestic requirements. "The Government has withdrawn the restrictions on 12 products and its formulations. Various scenarios are being assessed and it will be the endeavour to meet both the domestic demand and export obligation for Paracetamol and hydroxychloroquine," Jain said. The objective is to minimise speculative buying and hoarding in these trying times and ensure balance in the distribution for patients and segments who need them, he added. In a similar vein, Indian Drug Manufacturers' Association (IDMA) Executive Director Ashok Kumar Madan said: "India needs around 24 million tablets per year as on date for the three indications --- malaria, lupus, and rheumatoid arthritis, it was being used". India currently has an annual installed capacity of around 40 metric tonnes of active pharmaceutical ingredients (APIs) of hydroxychloroquine. With this capacity, "we can make around 200 million tablets of 200 mg", he added. So this indicates that India currently has spare available capacity. Now, "we have to see how much would the country's requirements for the drug would grow for both treatment and prevention of COVID-19. The companies have already started ramping the capacity." The major API makers for the drug in the country are Zydus, Ipca and Mangalam Drugs. The major formulation makers of hydroxychloroquine are Ipca, Zydus, Wallace Pharmaceuticals, and Cipla, Madan said. India exported hydroxychloroquine API in April-January 2019-20 period worth USD 1.22 billion. During the same period exports of formulations made from hydroxychloroquine were at USD 5.50 billion. Indian Council of Medical Research (ICMR) recommended HCQ be used as a preventive medication for COVID-19 high-risk group. It has also recommended the use of the drug for those involved in the care of 'suspected or confirmed cases of the coronavirus and for asymptomatic household contacts of laboratory-confirmed patients, apart from healthcare workers who are involved in the treatment of COVID-19'. Ipca is the drug's top manufacturer globally. Each COVID-19 patient reportedly needs 14 tablet course and so the 10 crore pills ordered by the government can potentially treat over 71 lakh people. AKT RR ANZ BAL

You Searched For "zydus wellness" and got 11 results

Zydus Wellness Q3 net profit at Rs 4 cr

PTI

COVID-19: Zydus Wellness launches hand sanitizer under Nycil brand to meet growing demand

PTI

Top stocks to watch— TCS, Future Consumer, ONGC, Zydus Wellness, HDFC, IL&FS, Angel Broking, Sun Pharma and others

Navdeep Yadav

Zydus Q4 net profit surges 4-fold to ₹1,182 cr; revenue at ₹5,534 cr

PTI

Zydus gets nod for human trials of COVID-19 vaccine

PTI

These 8 valuable companies rule their sectors with a huge piece of the pie

Bhakti Makwana

Zydus says potential COVID-19 vaccine gets DGCI nod for human trials

PTI

Zydus Cadila launches research prog to develop vaccine for coronavirus

PTI

Enough capacity in country to meet hydroxychloroquine demand: Industry

PTI

Zydus Cadila gets DCGI nod for Phase I trial of new drug aimed to treat rheumatoid arthritis

PTI

India biggest producer of 'game-changer' hydroxychloroquine drug; has enough capacity

PTI

Popular Keywords

Buying Guides